Skip to main content
. 2021 Feb 20;6(9):2841–2853. doi: 10.1016/j.bioactmat.2021.02.007

Fig. 2.

Fig. 2

MiR-31-5p regulates endothelial cells, fibroblasts and epithelial cells via the HIF pathway and EMP-1. (A) miR-31-5p target prediction according to StarBase, miRDB and TargetScan; miR-31-5p endothelial cells, fibroblasts and epithelial cells regulating targets found by intersections of possible miR-31-5p targets and the anti-angiogenesis gene pool, anti-fibroblast gene pool or anti-reepithelization gene pool; (B) miR-31-5p inhibition of HIF1AN and EMP-1 as detected by luciferase assays; (C) western blotting shows HIF1AN, VEGF and EMP-1 expression in ECs, HFF-1 cells and HaCaT cells with miR-31-5p-mimic and si-HIF1A treatment; (D) EC and HFF-1 cell migration and EC tube formation under treatment with miR-31-5p-mimic and si-HIF1A; (E) EC and HFF-1 cell proliferation under treatment with miR-31-5p-mimic and si-HIF1A. *Significant difference compared with control (p < 0.05); **significant difference compared with control (p < 0.01); ***significant difference compared with control (p < 0.001); ****significant difference compared with control (p < 0.0001); # significant difference compared with miR-31-5p mimic (p < 0.05); ## significant difference compared with miR-31-5p mimic (p < 0.01); ### significant difference compared with miR-31-5p mimic (p < 0.001); #### significant difference compared with miR-31-5p mimic (p < 0.0001).